Morning Trend | Nuvalent consolidates at a low level, is it time to switch the main line of innovative drug counterattack?

Nuvalent (NUVL.US) has recently maintained a low-level oscillation and consolidation, with the innovative drug sector overall in a repeated bottom-seeking phase. However, funds for low buying have already taken action, and many in the trading community are eager for the innovative drug mainline to "counterattack." Currently, there are no significant news from the company, but potential support may come from R&D progress and new drug dynamics in the industry, with the sector's market sentiment ready to switch direction at any time. From the market perspective, main funds are dragging and oscillating at low levels, with existing funds trading amidst long and short divergences. Mainstream technical indicators have shown a bottom structure, and large funds are just waiting for a long bullish candle to ignite market sentiment. The innovative drug sub-sector has always been a target for speculative funds, and once there are breakthroughs in R&D, approval progress, or favorable policies that create a "windfall," a short-term explosive performance from Nuvalent is highly likely. The overall pattern could shift from weak to strong at any time, with defensive funds ready to switch to offensive. It is recommended to closely monitor sector movements, main fund dynamics, and policy-related news, as Nuvalent may switch between offense and defense after consolidating. Fast-paced traders who enjoy capturing thematic rotations often find such consolidation followed by sudden surges to be stimulating